Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1998 Jan;78(1):54–57. doi: 10.1136/adc.78.1.54

Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus

S Volti 1, M Caruso-Nicoletti 1, F Biazzo 1, A Sciacca 1, G Mandara 1, M Mancuso 1, F Mollica 1
PMCID: PMC1717427  PMID: 9534677

Abstract

The immune response to intradermal or intramuscular hepatitis B vaccine in 18 children with insulin dependent diabetes mellitus (IDDM) compared with 24 healthy children was studied. Patients were divided into responders, hyporesponders, and non-responders according to their antihepatitis B serum concentrations after hepatitis B vaccination. We also studied HLA class II antigen distribution and did delayed type hypersensitivity (DTH) tests on children with IDDM and controls.
 No difference in the immune response (antihepatitis B surface antigen antibody titres) was found with intramuscular administration, whereas with intradermal administration a statistically lower immune response (p < 0.001) was observed in children with IDDM v controls. This hyporesponsiveness cannot be attributed to HLA class II antigen distribution because their frequency was the same in both groups of children with IDDM.
 It is suggested that the poor immune response to intradermal hepatitis B vaccine may be due to impaired macrophage activity resulting in failure of antigen presentation, which may be of importance in the immune dysfunction in children with IDDM. This hypothesis is suggested by a significantly lower score on a DTH test to a battery of antigens in the IDDM group when compared with controls. It is therefore suggested that when the hepatitis B vaccination is offered to children with IDDM it may be preferable to give it intramuscularly.



Full Text

The Full Text of this article is available as a PDF (87.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Kruskall M. S., Marcus-Bagley D., Craven D. E., Katz A. J., Brink S. J., Dienstag J. L., Awdeh Z., Yunis E. J. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med. 1989 Sep 14;321(11):708–712. doi: 10.1056/NEJM198909143211103. [DOI] [PubMed] [Google Scholar]
  2. Drell D. W., Notkins A. L. Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987 Mar;30(3):132–143. doi: 10.1007/BF00274217. [DOI] [PubMed] [Google Scholar]
  3. Egea E., Iglesias A., Salazar M., Morimoto C., Kruskall M. S., Awdeh Z., Schlossman S. F., Alper C. A., Yunis E. J. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med. 1991 Mar 1;173(3):531–538. doi: 10.1084/jem.173.3.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Leonardi S., Leggio T., Sciacca A., Di Gregorio F., Musumeci S. Intradermal hepatitis B vaccination in thalassaemia. Arch Dis Child. 1990 May;65(5):527–529. doi: 10.1136/adc.65.5.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lorini R., Montagna D., Lanfranchi A., Cortona L., Livieri C., Larizza D., d'Annunzio G., Severi F. Alterations of in vitro interleukin 1 and 2 in diabetic children. Eur J Pediatr. 1989 Aug;148(8):732–734. doi: 10.1007/BF00443096. [DOI] [PubMed] [Google Scholar]
  6. Madaliński K., Brzosko W. J., Malczewski B., Czyzyk A. Au-H.A.A. in sera of diabetic patients. Lancet. 1971 Apr 3;1(7701):701–702. doi: 10.1016/s0140-6736(71)92708-5. [DOI] [PubMed] [Google Scholar]
  7. Miller K. D., Gibbs R. D., Mulligan M. M., Nutman T. B., Francis D. P. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet. 1983 Dec 24;2(8365-66):1454–1456. doi: 10.1016/s0140-6736(83)90800-0. [DOI] [PubMed] [Google Scholar]
  8. Nagafuchi S., Kashiwagi S., Okada K., Anzai K., Nakamura M., Nishimura Y., Sasazuki T., Niho Y. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA. 1991 May 22;265(20):2679–2683. [PubMed] [Google Scholar]
  9. Polish L. B., Shapiro C. N., Bauer F., Klotz P., Ginier P., Roberto R. R., Margolis H. S., Alter M. J. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. N Engl J Med. 1992 Mar 12;326(11):721–725. doi: 10.1056/NEJM199203123261101. [DOI] [PubMed] [Google Scholar]
  10. Pozzilli P., Arduini P., Visalli N., Sutherland J., Pezzella M., Galli C., Corradini S. G., Biasio L., Gale E. A., Andreani D. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia. 1987 Oct;30(10):817–819. doi: 10.1007/BF00275749. [DOI] [PubMed] [Google Scholar]
  11. Pozzilli P., Pagani S., Arduini P., Visalli N., Cioccia G. P., Negri M., Andreani D. In vivo determination of cell mediated immune response in diabetic patients using a multiple intradermal antigen dispenser. Diabetes Res. 1987 Sep;6(1):5–8. [PubMed] [Google Scholar]
  12. Pozzilli P., Zuccarini O., Iavicoli M., Andreani D., Sensi M., Spencer K. M., Bottazzo G. F., Beverley P. C., Kyner J. L., Cudworth A. G. Monoclonal antibodies defined abnormalities of T-lymphocytes in type I (insulin-dependent) diabetes. Diabetes. 1983 Jan;32(1):91–94. doi: 10.2337/diab.32.1.91. [DOI] [PubMed] [Google Scholar]
  13. Sahdev I., Fort P., Herry A. Macrophage-released interleukin-1 in patients with type 1 diabetes mellitus. Acta Paediatr. 1992 Nov;81(11):935–936. doi: 10.1111/j.1651-2227.1992.tb12140.x. [DOI] [PubMed] [Google Scholar]
  14. Sahdev I., Fort P., Herry A. Macrophage-released interleukin-1 in patients with type 1 diabetes mellitus. Acta Paediatr. 1992 Nov;81(11):935–936. doi: 10.1111/j.1651-2227.1992.tb12140.x. [DOI] [PubMed] [Google Scholar]
  15. Savagnone E. Studio multicentrico sul rischio infettivo del diabetico. Nota I. Correlazione tra alterato metabolismo glicidico e cutireattività al Multitest IMC. Minerva Endocrinol. 1991 Jul-Sep;16(3):119–125. [PubMed] [Google Scholar]
  16. Wismans P. J., van Hattum J., de Gast G. C., Bouter K. P., Diepersloot R. J., Maikoe T., Mudde G. C. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol. 1991 Nov;35(3):216–222. doi: 10.1002/jmv.1890350313. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES